<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742298</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00072199</org_study_id>
    <nct_id>NCT02742298</nct_id>
  </id_info>
  <brief_title>Pompe Disease QMUS and EIM</brief_title>
  <official_title>Electrical Impedance Myography and Muscle Ultrasound: Longitudinal Measures in Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives:

        1. Determine the correlation between quantitative muscle ultrasound (QMUS), electrical
           impedance myography (EIM) and currently accepted measures of physical function.

        2. Determine the reliability of EIM measures performed in the home through use of a hand
           held device.

        3. Determine if QMUS and EIM can detect pre-clinical changes in Pompe disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 24, 2016</start_date>
  <completion_date type="Anticipated">February 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in muscle ultrasound echointensity as compared to baseline</measure>
    <time_frame>Baseline, 1-2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in muscle electrical impedance myography as compared to baseline</measure>
    <time_frame>Baseline, 1-2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-rater reliability of muscle ultrasound and electrical impedance myography measures</measure>
    <time_frame>1-2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>QMUS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will undergo serial quantitative muscle ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EIM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will undergo serial electrical impedance myography measures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Muscle ultrasound</intervention_name>
    <description>Ultrasound images of limb muscles will be collected.</description>
    <arm_group_label>QMUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrical Impedance Myography</intervention_name>
    <description>A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.</description>
    <arm_group_label>EIM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed diagnosis of Pompe disease.

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa D Hobson-Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuromuscular Ultrasound</keyword>
  <keyword>Electrical Impedance Myography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

